Management of febrile neutropenia: ESMO Clinical Recommendations

被引：22

作者：

Marti, F. Marti ^{[1
]}

Cullen, M. H. ^{[1
]}

Roila, F. ^{[2
]}

机构：

[1] Univ Hosp Birmingham, Dept Med Oncol, NHS Fdn Trust, Birmingham, W Midlands, England

[2] S Maria Hosp, Dept Med Oncol, Terni, Italy

来源：

ANNALS OF ONCOLOGY | 2009年 / 20卷

关键词：

MULTINATIONAL-ASSOCIATION; ANTIBIOTIC-TREATMENT; SUPPORTIVE-CARE; CANCER-PATIENTS; RISK INDEX; METAANALYSIS; OUTPATIENT;

D O I：

10.1093/annonc/mdp163

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：166 / 169

页数：4

共 10 条

[1]

[Anonymous], COCHRANE DATABASE SY

[2] Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia [J].

Elting, Linda S. ;

Lu, Charles ;

Escalante, Carmelita P. ;

Giordano, Sharon H. ;

Trent, Jonathan C. ;

Cooksley, Catherine ;

Avritscher, Elenir B. C. ;

Shih, Ya-Chen Tina ;

Ensor, Joe ;

Bekele, B. Nebiyou ;

Gralla, Richard J. ;

Talcott, James A. ;

Rolston, Kenneth .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :606-611

[3] Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis [J].

Furno, P ;

Bucaneve, G ;

Del Favero, A .

LANCET INFECTIOUS DISEASES, 2002, 2 (04) :231-242

[4] Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy:: Causes and consequences [J].

Hamalainen, Sari ;

Kuittinen, Taru ;

Marinlauri, Irma ;

Nousiainen, Tapio ;

Koivula, Irma ;

Jantunen, Esa .

LEUKEMIA & LYMPHOMA, 2008, 49 (03) :495-501

[5] Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice [J].

Innes, Helen ;

Lim, Sheow Lei ;

Hall, Allison ;

Chan, Su Yin ;

Bhalla, Neeraj ;

Marshall, Ernest .

SUPPORTIVE CARE IN CANCER, 2008, 16 (05) :485-491

[6]

Innes H, 2007, CURR OPIN ONCOL, V19, P294

[7] Bacterial infections in low-risk, febrile neutropenic patients - Over a decade of experience at a comprehensive cancer center [J].

Kamana, M ;

Escalante, C ;

Mullen, CA ;

Frisbee-Hume, S ;

Rolston, KVI .

CANCER, 2005, 104 (02) :422-426

[8] Pathogen 'shift' in febrile neutropenia [J].

Kibbler, CC ;

Prentice, HG .

CURRENT OPINION IN INFECTIOUS DISEASES, 1999, 12 (04) :351-354

[9] The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients [J].

Klastersky, J ;

Paesmans, M ;

Rubenstein, EB ;

Boyer, M ;

Elting, L ;

Feld, R ;

Gallagher, J ;

Herrstedt, J ;

Rapoport, B ;

Rolston, K ;

Talcott, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :3038-3051

[10] Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials [J].

Vidal, L ;

Paul, M ;

Ben dor, I ;

Soares-Weiser, K ;

Leibovici, L .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) :29-37

← 1 →